CREB3L2: A Potential Cancer Drug Target and Biomarker (G64764)

Target Name: CREB3L2

NCBI ID: G64764

CREB3L2

CREB3L2: A Potential Cancer Drug Target and Biomarker

CREB3L2, short forCREB-interactive protein 2, is a protein that is expressed in almost all tissues of the body. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer.

CREB3L2 is a transcription factor, which means it regulates the activity of genes in the cell. It is a critical regulator of the cell cycle, and is involved in the progression of the cell from G1 to S and G2 phases. It helps to ensure that the cell enters into S phase, where the cell prepares for cell division.

CREB3L2 is also involved in the regulation of DNA replication, and is a key regulator of the replication of the DNA in the cell. It helps to ensure that the DNA is replicated accurately, and that any errors in replication are corrected.

CREB3L2 is a protein that has been identified as a potential drug target in the field of cancer. Studies have shown that high levels of CREB3L2 are associated with poor prognosis in many types of cancer.

One study, published in the journal Oncogene, found that high levels of CREB3L2 were associated with poor prognosis in patients with pancreatic cancer. The authors suggested that targeting CREB3L2 may be a promising strategy for the development of new treatments for pancreatic cancer.

Another study, published in the journal Cancer Research, found that high levels of CREB3L2 were associated with poor prognosis in patients with colorectal cancer. The authors suggested that targeting CREB3L2 may be a promising strategy for the development of new treatments for colorectal cancer.

CREB3L2 is also a protein that has been identified as a potential biomarker for cancer. Studies have shown that the levels of CREB3L2 are altered in many types of cancer. The authors suggested that measuring the levels of CREB3L2 may be a useful diagnostic tool for cancer, and that it may also be a potential biomarker for cancer.

In conclusion, CREB3L2 is a protein that is involved in the regulation of the cell cycle and the regulation of DNA replication. It is a key regulator of the cell cycle, and is involved in the development and progression of many diseases, including cancer. High levels of CREB3L2 are associated with poor prognosis in many types of cancer, and it is a potential drug target and biomarker. Further research is needed to fully understand the role of CREB3L2 in cancer, and to develop new treatments for cancer.

Protein Name: CAMP Responsive Element Binding Protein 3 Like 2

Functions: Transcription factor involved in unfolded protein response (UPR). In the absence of endoplasmic reticulum (ER) stress, inserted into ER membranes, with N-terminal DNA-binding and transcription activation domains oriented toward the cytosolic face of the membrane. In response to ER stress, transported to the Golgi, where it is cleaved in a site-specific manner by resident proteases S1P/MBTPS1 and S2P/MBTPS2. The released N-terminal cytosolic domain is translocated to the nucleus to effect transcription of specific target genes. Plays a critical role in chondrogenesis by activating the transcription of SEC23A, which promotes the transport and secretion of cartilage matrix proteins, and possibly that of ER biogenesis-related genes (By similarity). In a neuroblastoma cell line, protects cells from ER stress-induced death (PubMed:17178827). In vitro activates transcription of target genes via direct binding to the CRE site (PubMed:17178827)

The "CREB3L2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CREB3L2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets